Biofrontera Inc. is a biopharmaceutical company specializing in the research, development, and commercialization of dermatological treatments, particularly focusing on skin cancer and other dermatological conditions. Founded in Germany in 1997, the company has expanded its operations to the United States, where Biofrontera Inc. serves as its U.S. subsidiary, headquartered in Woburn, Massachusetts.
At the core of Biofrontera's portfolio is its proprietary drug, Ameluz®, which contains the active ingredient aminolevulinic acid (ALA). Ameluz® is used in photodynamic therapy (PDT), a non-invasive treatment for actinic keratosis, a common pre-cancerous skin condition, and basal cell carcinoma, the most common type of skin cancer. The company's focus on targeted treatments aligns with the growing demand for precise and effective dermatological therapies.
The company's commitment to innovation is evident in its pursuit of advancing PDT technology. Biofrontera invests in clinical research to demonstrate the safety and efficacy of its treatments and explores the potential applications of its products in addressing other dermatological disorders.
Biofrontera's presence extends beyond product development; the company is dedicated to educating medical professionals and patients about skin cancer prevention, early detection, and treatment options. By fostering awareness and providing resources, the company aims to contribute to improved patient outcomes.